scholarly journals Exploring the frontier of cardiovascular pharmacotherapy

2021 ◽  
Vol 41 (12) ◽  
pp. 968-969
Author(s):  
William L. Baker ◽  
Cynthia A. Jackevicius
Keyword(s):  
Cardiovascular Pharmacotherapy

Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction

2005 ◽  
Vol 98 (1) ◽  
pp. 1-14 ◽  
Author(s):  
Angelo A. Izzo ◽  
Giulia Di Carlo ◽  
Francesca Borrelli ◽  
Edzard Ernst
Keyword(s):  
Drug Interaction ◽  
Herbal Medicines ◽  
Cardiovascular Pharmacotherapy

scholarly journals Cardiovascular pharmacotherapy in childhood

2019 ◽  
Vol 15 (2) ◽  
pp. 77-81
Author(s):  
Karel Koubský ◽  
Jan Janoušek ◽  
Václav Chaloupecký
Keyword(s):  
Cardiovascular Pharmacotherapy

Combination Drug Therapy: A Strategy for Aggressive Lipid Modification

2005 ◽  
Vol 40 (11) ◽  
pp. 954-962
Author(s):  
James M. Backes ◽  
Patricia A. Howard
Keyword(s):  
Cardiovascular Disease ◽  
Drug Therapy ◽  
Clinical Outcome ◽  
Combination Drug Therapy ◽  
Lipid Modification ◽  
Combination Drug ◽  
Cardiovascular Pharmacotherapy ◽  
The Us ◽  
Prevention And Treatment ◽  
Recent Developments

This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on prevention and treatment — if they keep current with developments in drug therapy.

scholarly journals Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

2019 ◽  
Vol 6 (2) ◽  
pp. 104-114 ◽  
Author(s):  
Ivana Hollan ◽  
Nicoletta Ronda ◽  
Patrick Dessein ◽  
Stefan Agewall ◽  
George Karpouzas ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Prevention ◽  
Optimal Strategies ◽  
Position Paper ◽  
Related Factors ◽  
Lipid Management ◽  
Expert Opinions ◽  
Cardiovascular Pharmacotherapy ◽  
European Society Of Cardiology ◽  
Lipid Parameters

Abstract Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity, partly due to alterations in lipoprotein quantity, quality and cell cholesterol trafficking. Although cardiovascular disease significantly contributes to mortality excess in RA, cardiovascular prevention has been largely insufficient. Because of limited evidence, optimal strategies for lipid management (LM) in RA have not been determined yet, and recommendations are largely based on expert opinions. In this position paper, we describe abnormalities in lipid metabolism and introduce a new algorithm for estimation of cardiovascular risk (CVR) and LM in RA. The algorithm stratifies patients according to RA-related factors impacting CVR (such as RA activity and severity and medication). We propose strategies for monitoring of lipid parameters and treatment of dyslipidaemia in RA (including lifestyle, statins and other lipid-modifying therapies, and disease modifying antirheumatic drugs). These opinion-based recommendations are meant to facilitate LM in RA until more evidence is available.

The Evolving Role of Angiotensin Receptor Blockers in Heart Failure

2002 ◽  
Vol 37 (5) ◽  
pp. 474-482
Author(s):  
Patricia A. Howard
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Cardiovascular Pharmacotherapy ◽  
The Us ◽  
Prevention And Treatment ◽  
Recent Developments ◽  
Receptor Blockers

This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on the prevention and treatment of cardiovascular disease—if they keep current with developments in drug therapy.

scholarly journals The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials

2019 ◽  
Vol 6 (2) ◽  
pp. 97-103 ◽  
Author(s):  
Heinz Drexel ◽  
Giuseppe M C Rosano ◽  
Basil S Lewis ◽  
Kurt Huber ◽  
Alexander Vonbank ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Gold Standard ◽  
Randomized Clinical Trials ◽  
Clinical Endpoints ◽  
Cardiovascular Pharmacotherapy ◽  
Total Event

Abstract Randomized clinical trials (RCTs) are important and the Gold Standard for drugs in modern cardiovascular (CV) therapy. The cornerstone of RCTs is the recording of hard clinical endpoints instead of surrogates. It is important to select an appropriate endpoint. Efficacy endpoints must be clinically relevant and can be hierarchically divided. A very interesting innovation in endpoint acquisition is the total event paradigm.

Sign in / Sign up

Export Citation Format

Share Document